

MyOwnMed ECOS System News

FOR IMMEDIATE RELEASE

The immediate impacts of COVID-19 are increasingly documented and understood, however, the long-term consequences of infection and recovery are still unknown. To address these questions, My Own Med, Inc. (MyOwnMed) is playing an important role in support of the new NIH IMPACC (IMMunoPhenotyping Assessment in a COVID-19 Cohort) study. The IMPACC study will use the MyOwnMed ECOS Mobile app, a comprehensive digital remote monitoring tool, to capture direct-from-patient, real-world evidence and will access important data and custom analytics through the MyOwnMed ECOS Portal.

IMPACC, sponsored by the National Institute of Allergy and Infectious Diseases, will enroll up to 2,000 COVID-19-infected, post-hospitalization patients at 10 leading medical centers across the United States, seeking to learn how their immune systems respond over time. The MyOwnMed ECOS Platform will serve as an ongoing way of tracking patient-reported of physical, mental and social health recovery statistics.

Moving forward, the ECOS Mobile app, containing a COVID-19 symptom tracker will be utilized over the course of the one-year follow-up study as a patient-centric remote digital tool to monitor and address any persistent COVID-like symptoms. The patient-reported data will be used to correlate with over 200,000 collected samples to measure immune system responses aimed to help understand and guide treatments for COVID-19 recovery.

“We look forward to working with MyOwnMed and harnessing our expertise in infectious diseases to garner critically important insights into why some patients fare better than others against this devastating disease.” Charles B. Cairns, MD, FACEP, FAAEM, FAHA Walter H. and Leonore Annenberg Dean and Senior Vice President of Medical Affairs | Drexel University’s College of Medicine

MyOwnMed will be working with Dr. Charles Cairns, Dean of Drexel University College of Medicine and Dr. Albert Ozonoff and his team at the National IMPACC Clinical & Data Coordinating Center (CDCC) located at Boston Children’s Hospital. *“The information we learn will allow us to study the relationship between the immune system and clinical aspects of the disease,”* says Ozonoff. *“We believe it will be a powerful way to discover bio-markers, or molecules in the body that may help predict disease severity and even patient outcomes.”*

ADDITIONAL INFORMATION

IMPACC Study and Participation: [clinicaltrials.gov](https://clinicaltrials.gov/ct2/show/study/NCT04378777)
(ID: NCT04378777)

MyOwnMed ECOS System: myownmed.com



We are a team of experts with decades of experience in immunology, science, clinical trials, health care policy, and medical product regulation, regulatory policy, and science expertise spanning development of bio-marker discovery and validation, advanced data mining and analytics, and extensive experience in clinical trials.

My Own Med, Inc.
info@myownmed.com
(240) 356-1008
myownmed.com